AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Conditions
Brief summary
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients. Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.
Interventions
DRUGAntiVEGF
anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
DRUGICIs
immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
Sponsors
First Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>=20yr; * Patients must have at least one Evaluation and Managementvisit with a diagnosis of cancer within 12 months before index date (In situ biopsy will not be required, since patients may receive a diagnosis from a biopsy of metastatic site); * Indication to initiate AntiVEGF or ICIs
Exclusion criteria
* Patients without valid data and less than 3 months followup; * Patients without baseline Scr value within 12 mon before index date; * Patients with combination therapy of Anti-VEGF and ICIs ; * Patients with chronic renal failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| accumulative incidence of sustained AKI | 12 months after index date | sustained AKI will be defined as the elevation ≥1.5 times baseline sCr for ≥72hours according to the Kidney Disease Improving Global Outcomes (KDIGO) sCr criteria |
Countries
China
Outcome results
None listed